BlackRock Fund Advisors’s Cidara Therapeutics CDTX Stock Holding History

BlackRock Fund Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.44M	Buy	21,343 +6,271	+42%	+$1.3M	﹤0.01%	2984
2016 Q3	$3.45M	Buy	15,072 +1,310	+10%	+$303K	﹤0.01%	3022
2016 Q2	$2.84M	Buy	13,762 +7,606	+124%	+$1.84M	﹤0.01%	3095
2016 Q1	$1.56M	Sell	6,156 -357	-5%	-$82.3K	﹤0.01%	3128
2015 Q4	$2.23M	Buy	6,513 +57	+0.9%	+$17.1K	﹤0.01%	3123
2015 Q3	$1.64M	Buy	6,456 +49	+0.8%	+$14K	﹤0.01%	3153
2015 Q2	$1.8M	Buy	+6,407	New	+$1.97M	﹤0.01%	3177

Other funds holding CDTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock Fund Advisors's CDTX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Cidara Therapeutics (CDTX) stake by 42% in Q4 2016, buying an estimated $1.3M and bringing the position to 21,343 shares worth $4.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2984.

BlackRock Fund Advisors first reported a position in CDTX in Q2 2015 and has held it in 7 quarters since. 58 funds tracked by Wall St. Rank hold CDTX as of Q4 2016.

BlackRock Fund Advisors held 21,343 shares of Cidara Therapeutics worth $4.44M as of Q4 2016.
BlackRock Fund Advisors bought 6,271 Cidara Therapeutics shares in Q4 2016, an estimated $1.3M.
Cidara Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2984 holding.
BlackRock Fund Advisors first reported a position in Cidara Therapeutics in Q2 2015 and has held it in 7 quarters since.
58 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.